Isorhamnetin protects against cardiac hypertrophy through blocking PI3K–AKT pathway

Novel Role for Caspase-Activated DNase in the Regulation of Pathological Cardiac Hypertrophy

(2015) L. Gao et al.   HYPERTENSION

Isorhamnetin Attenuates Atherosclerosis by Inhibiting Macrophage Apoptosis via PI3K/AKT Activation and HO-1 Induction

(2015) Yun Luo et al.   PLoS One

Vinexin-β protects against cardiac hypertrophy by blocking the Akt-dependent signalling pathway

(2013) Ke Chen et al.   BASIC RESEARCH IN CARDIOLOGY

Growth/differentiation factor 1 alleviates pressure overload-induced cardiac hypertrophy and dysfunction

(2013) Yan Zhang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

O-methylated flavonol isorhamnetin prevents acute inflammation through blocking of NF-κB activation

(2013) Ji Hye Yang et al.   FOOD AND CHEMICAL TOXICOLOGY

Role of Interferon Regulatory Factor 4 in the Regulation of Pathological Cardiac Hypertrophy

(2013) Ding-Sheng Jiang et al.   HYPERTENSION

Interferon Regulatory Factor 9 Protects Against Cardiac Hypertrophy by Targeting Myocardin

(2013) Ding-Sheng Jiang et al.   HYPERTENSION

Isorhamnetin Protects against Doxorubicin-Induced Cardiotoxicity In Vivo and In Vitro

(2013) Jing Sun et al.   PLoS One

Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes

(2013) Ji Hye Yang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

mTOR signalling: the molecular interface connecting metabolic stress, aging and cardiovascular diseases

(2012) Z. Yang et al.   Obesity Reviews

Isorhamnetin Suppresses Skin Cancer through Direct Inhibition of MEK1 and PI3-K

(2011) J.-E. Kim et al.   Cancer Prevention Research

Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure

(2011) Toshinori Aoyagi et al.   CURRENT PHARMACEUTICAL DESIGN

Isorhamnetin inhibits H2O2-induced activation of the intrinsic apoptotic pathway in H9c2 cardiomyocytes through scavenging reactive oxygen species and ERK inactivation

(2011) Bing Sun et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways

(2011) C.F.M.Z. Clemente et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Reverse remodeling in heart failure—mechanisms and therapeutic opportunities

(2011) Norimichi Koitabashi et al.   Nature Reviews Cardiology

Novel therapeutic targets for the treatment of heart failure

(2011) Juan Tamargo et al.   NATURE REVIEWS DRUG DISCOVERY

The Role of MEKK1 in Hypertrophic Cardiomyopathy

(2010) John P. Konhilas et al.   International Heart Journal

Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling

(2010) Wen Ai et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Isorhamnetin protects rat ventricular myocytes from ischemia and reperfusion injury

(2009) Najuan Zhang et al.   EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY

LY294002 inhibits leukemia cell invasion and migration through early growth response gene 1 induction independent of phosphatidylinositol 3-kinase-Akt pathway

(2008) Peng Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis

(2008) P H Sugden et al.   BRITISH JOURNAL OF PHARMACOLOGY

Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3β signaling

(2008) Qizhu Tang et al.   JOURNAL OF MOLECULAR MEDICINE-JMM